Tumor  ||| S:0 E:6 ||| NN
size  ||| S:6 E:11 ||| NN
is  ||| S:11 E:14 ||| VBZ
an  ||| S:14 E:17 ||| DT
independent  ||| S:17 E:29 ||| JJ
predictor  ||| S:29 E:39 ||| NN
of  ||| S:39 E:42 ||| IN
lymph  ||| S:42 E:48 ||| JJ
node  ||| S:48 E:53 ||| JJ
metastasis  ||| S:53 E:64 ||| NN
and  ||| S:64 E:68 ||| CC
survival  ||| S:68 E:77 ||| NN
in  ||| S:77 E:80 ||| IN
early  ||| S:80 E:86 ||| JJ
stage  ||| S:86 E:92 ||| NN
endometrioid  ||| S:92 E:105 ||| VBZ
endometrial  ||| S:105 E:117 ||| JJ
cancer  ||| S:117 E:124 ||| NN
To  ||| S:124 E:127 ||| TO
analyze  ||| S:127 E:135 ||| VB
the  ||| S:135 E:139 ||| DT
impact  ||| S:139 E:146 ||| NN
of  ||| S:146 E:149 ||| IN
tumor  ||| S:149 E:155 ||| NN
size  ||| S:155 E:160 ||| NN
( ||| S:160 E:161 ||| -LRB-
TS ||| S:161 E:163 ||| NNP
)  ||| S:163 E:165 ||| -RRB-
on  ||| S:165 E:168 ||| IN
risk  ||| S:168 E:173 ||| NN
of  ||| S:173 E:176 ||| IN
lymph  ||| S:176 E:182 ||| FW
node  ||| S:182 E:187 ||| FW
metastasis  ||| S:187 E:198 ||| FW
( ||| S:198 E:199 ||| -LRB-
PLN ||| S:199 E:202 ||| NNP
)  ||| S:202 E:204 ||| -RRB-
and  ||| S:204 E:208 ||| CC
prognosis  ||| S:208 E:218 ||| NN
in  ||| S:218 E:221 ||| IN
endometrioid  ||| S:221 E:234 ||| JJ
endometrial  ||| S:234 E:246 ||| JJ
cancer  ||| S:246 E:253 ||| NN
grossly  ||| S:253 E:261 ||| RB
confined  ||| S:261 E:270 ||| VBN
to  ||| S:270 E:273 ||| TO
the  ||| S:273 E:277 ||| DT
uterus  ||| S:277 E:284 ||| NN
( ||| S:284 E:285 ||| -LRB-
EEC ||| S:285 E:288 ||| NNP
) ||| S:288 E:289 ||| -RRB-
.  ||| S:289 E:291 ||| .
Patients  ||| S:291 E:300 ||| NNS
with  ||| S:300 E:305 ||| IN
EEC  ||| S:305 E:309 ||| NNP
grossly  ||| S:309 E:317 ||| RB
confined  ||| S:317 E:326 ||| VBN
to  ||| S:326 E:329 ||| TO
the  ||| S:329 E:333 ||| DT
uterus  ||| S:333 E:340 ||| NN
were  ||| S:340 E:345 ||| VBD
identified  ||| S:345 E:356 ||| VBN
from  ||| S:356 E:361 ||| IN
Surveillance ||| S:361 E:373 ||| NNP
,  ||| S:373 E:375 ||| ,
Epidemiology ||| S:375 E:387 ||| NNP
,  ||| S:387 E:389 ||| ,
and  ||| S:389 E:393 ||| CC
End  ||| S:393 E:397 ||| NN
Results  ||| S:397 E:405 ||| NNS
dataset  ||| S:405 E:413 ||| VBN
from  ||| S:413 E:418 ||| IN
1988  ||| S:418 E:423 ||| CD
to  ||| S:423 E:426 ||| TO
2007 ||| S:426 E:430 ||| CD
.  ||| S:430 E:432 ||| .
Only  ||| S:432 E:437 ||| RB
surgically  ||| S:437 E:448 ||| RB
treated  ||| S:448 E:456 ||| VBN
patients  ||| S:456 E:465 ||| NNS
were  ||| S:465 E:470 ||| VBD
included ||| S:470 E:478 ||| VBN
.  ||| S:478 E:480 ||| .
TS  ||| S:480 E:483 ||| NNP
was  ||| S:483 E:487 ||| VBD
analyzed  ||| S:487 E:496 ||| VBN
as  ||| S:496 E:499 ||| IN
a  ||| S:499 E:501 ||| DT
continuous  ||| S:501 E:512 ||| JJ
and  ||| S:512 E:516 ||| CC
categorical  ||| S:516 E:528 ||| JJ
variable  ||| S:528 E:537 ||| NNS
( ||| S:537 E:538 ||| -LRB-
TS  ||| S:538 E:541 ||| NNP
≤  ||| S:541 E:543 ||| CD
2  ||| S:543 E:545 ||| CD
cm ||| S:545 E:547 ||| NN
,  ||| S:547 E:549 ||| ,
> ||| S:549 E:550 ||| CD
2-5  ||| S:550 E:554 ||| CD
cm  ||| S:554 E:557 ||| NNS
and  ||| S:557 E:561 ||| CC
> ||| S:561 E:562 ||| CD
5  ||| S:562 E:564 ||| CD
cm ||| S:564 E:566 ||| CD
) ||| S:566 E:567 ||| -RRB-
.  ||| S:567 E:569 ||| .
Multivariable  ||| S:569 E:583 ||| JJ
logistic  ||| S:583 E:592 ||| JJ
regression  ||| S:592 E:603 ||| NN
and  ||| S:603 E:607 ||| CC
Cox  ||| S:607 E:611 ||| NNP
proportional  ||| S:611 E:624 ||| VBD
hazards  ||| S:624 E:632 ||| JJ
models  ||| S:632 E:639 ||| NNS
were  ||| S:639 E:644 ||| VBD
used.  ||| S:644 E:650 ||| CD
19,692  ||| S:650 E:657 ||| CD
patients  ||| S:657 E:666 ||| NNS
met  ||| S:666 E:670 ||| VBD
the  ||| S:670 E:674 ||| DT
inclusion  ||| S:674 E:684 ||| NN
criteria ||| S:684 E:692 ||| NNS
.  ||| S:692 E:694 ||| .
In  ||| S:694 E:697 ||| IN
patients  ||| S:697 E:706 ||| NNS
with  ||| S:706 E:711 ||| IN
TS  ||| S:711 E:714 ||| NNP
≤  ||| S:714 E:716 ||| CD
2  ||| S:716 E:718 ||| CD
cm ||| S:718 E:720 ||| NN
,  ||| S:720 E:722 ||| ,
only  ||| S:722 E:727 ||| RB
2.7  ||| S:727 E:731 ||| CD
%  ||| S:731 E:733 ||| NN
( ||| S:733 E:734 ||| -LRB-
88 ||| S:734 E:736 ||| CD
/ ||| S:736 E:737 ||| CD
3,244 ||| S:737 E:742 ||| CD
)  ||| S:742 E:744 ||| -RRB-
had  ||| S:744 E:748 ||| VBD
PLN ||| S:748 E:751 ||| NNP
;  ||| S:751 E:753 ||| :
this  ||| S:753 E:758 ||| DT
increased  ||| S:758 E:768 ||| VBN
to  ||| S:768 E:771 ||| TO
5.8  ||| S:771 E:775 ||| CD
%  ||| S:775 E:777 ||| NN
( ||| S:777 E:778 ||| -LRB-
372 ||| S:778 E:781 ||| CD
/ ||| S:781 E:782 ||| CD
6,355 ||| S:782 E:787 ||| CD
)  ||| S:787 E:789 ||| -RRB-
with  ||| S:789 E:794 ||| IN
TS  ||| S:794 E:797 ||| NNP
>  ||| S:797 E:799 ||| CD
2-5  ||| S:799 E:803 ||| CD
cm  ||| S:803 E:806 ||| NNS
and  ||| S:806 E:810 ||| CC
11.1  ||| S:810 E:815 ||| CD
%  ||| S:815 E:817 ||| NN
( ||| S:817 E:818 ||| -LRB-
195 ||| S:818 E:821 ||| CD
/ ||| S:821 E:822 ||| CD
1,745 ||| S:822 E:827 ||| CD
)  ||| S:827 E:829 ||| -RRB-
with  ||| S:829 E:834 ||| IN
TS  ||| S:834 E:837 ||| NNP
>  ||| S:837 E:839 ||| CD
5  ||| S:839 E:841 ||| CD
cm ||| S:841 E:843 ||| NNS
.  ||| S:843 E:845 ||| .
The  ||| S:845 E:849 ||| DT
odds  ||| S:849 E:854 ||| NNS
of  ||| S:854 E:857 ||| IN
PLN  ||| S:857 E:861 ||| NNP
increased  ||| S:861 E:871 ||| VBD
by  ||| S:871 E:874 ||| IN
14  ||| S:874 E:877 ||| CD
%  ||| S:877 E:879 ||| NN
for  ||| S:879 E:883 ||| IN
each  ||| S:883 E:888 ||| DT
1  ||| S:888 E:890 ||| CD
cm  ||| S:890 E:893 ||| JJ
increase  ||| S:893 E:902 ||| NN
in  ||| S:902 E:905 ||| IN
TS  ||| S:905 E:908 ||| NNP
after  ||| S:908 E:914 ||| IN
controlling  ||| S:914 E:926 ||| VBG
for  ||| S:926 E:930 ||| IN
age ||| S:930 E:933 ||| NN
,  ||| S:933 E:935 ||| ,
race ||| S:935 E:939 ||| NN
,  ||| S:939 E:941 ||| ,
depth  ||| S:941 E:947 ||| NN
of  ||| S:947 E:950 ||| IN
myometrial  ||| S:950 E:961 ||| JJ
invasion  ||| S:961 E:970 ||| NN
and  ||| S:970 E:974 ||| CC
grade  ||| S:974 E:980 ||| NN
( ||| S:980 E:981 ||| -LRB-
HR  ||| S:981 E:984 ||| NNP
1.14 ||| S:984 E:988 ||| CD
,  ||| S:988 E:990 ||| ,
95  ||| S:990 E:993 ||| CD
%  ||| S:993 E:995 ||| NN
CI  ||| S:995 E:998 ||| NNP
1.10-1.19 ||| S:998 E:1007 ||| NNP
,  ||| S:1007 E:1009 ||| ,
p  ||| S:1009 E:1011 ||| CD
< ||| S:1011 E:1013 ||| SYM
0.001 ||| S:1013 E:1018 ||| CD
) ||| S:1018 E:1019 ||| -RRB-
.  ||| S:1019 E:1021 ||| .
Further ||| S:1021 E:1028 ||| RB
,  ||| S:1028 E:1030 ||| ,
TS  ||| S:1030 E:1033 ||| NNP
was  ||| S:1033 E:1037 ||| VBD
an  ||| S:1037 E:1040 ||| DT
independent  ||| S:1040 E:1052 ||| JJ
predictor  ||| S:1052 E:1062 ||| NN
of  ||| S:1062 E:1065 ||| IN
disease-specific  ||| S:1065 E:1082 ||| JJ
survival  ||| S:1082 E:1091 ||| NN
( ||| S:1091 E:1092 ||| -LRB-
DSS ||| S:1092 E:1095 ||| NNP
)  ||| S:1095 E:1097 ||| -RRB-
even  ||| S:1097 E:1102 ||| RB
after  ||| S:1102 E:1108 ||| IN
adjusting  ||| S:1108 E:1118 ||| VBG
for  ||| S:1118 E:1122 ||| IN
age ||| S:1122 E:1125 ||| NN
,  ||| S:1125 E:1127 ||| ,
race ||| S:1127 E:1131 ||| NN
,  ||| S:1131 E:1133 ||| ,
grade ||| S:1133 E:1138 ||| NN
,  ||| S:1138 E:1140 ||| ,
depth  ||| S:1140 E:1146 ||| NN
of  ||| S:1146 E:1149 ||| IN
myometrial  ||| S:1149 E:1160 ||| JJ
invasion ||| S:1160 E:1168 ||| NN
,  ||| S:1168 E:1170 ||| ,
lymph  ||| S:1170 E:1176 ||| FW
node  ||| S:1176 E:1181 ||| FW
status  ||| S:1181 E:1188 ||| FW
and  ||| S:1188 E:1192 ||| CC
adjuvant  ||| S:1192 E:1201 ||| JJ
radiation  ||| S:1201 E:1211 ||| NN
therapy  ||| S:1211 E:1219 ||| NN
( ||| S:1219 E:1220 ||| -LRB-
HR  ||| S:1220 E:1223 ||| NNP
1.13  ||| S:1223 E:1228 ||| CD
for  ||| S:1228 E:1232 ||| IN
each  ||| S:1232 E:1237 ||| DT
1  ||| S:1237 E:1239 ||| CD
cm  ||| S:1239 E:1242 ||| JJ
increment  ||| S:1242 E:1252 ||| NN
in  ||| S:1252 E:1255 ||| IN
TS ||| S:1255 E:1257 ||| NNP
,  ||| S:1257 E:1259 ||| ,
95  ||| S:1259 E:1262 ||| CD
%  ||| S:1262 E:1264 ||| NN
1.08-1.18 ||| S:1264 E:1273 ||| NN
,  ||| S:1273 E:1275 ||| ,
p  ||| S:1275 E:1277 ||| CD
< ||| S:1277 E:1279 ||| SYM
0.001 ||| S:1279 E:1284 ||| CD
) ||| S:1284 E:1285 ||| -RRB-
.  ||| S:1285 E:1287 ||| .
In  ||| S:1287 E:1290 ||| IN
multivariable  ||| S:1290 E:1304 ||| JJ
analysis ||| S:1304 E:1312 ||| NN
,  ||| S:1312 E:1314 ||| ,
larger  ||| S:1314 E:1321 ||| JJR
TS  ||| S:1321 E:1324 ||| NNP
( ||| S:1324 E:1325 ||| -LRB-
> ||| S:1325 E:1326 ||| CD
5  ||| S:1326 E:1328 ||| CD
cm ||| S:1328 E:1330 ||| CD
)  ||| S:1330 E:1332 ||| -RRB-
was  ||| S:1332 E:1336 ||| VBD
significantly  ||| S:1336 E:1350 ||| RB
associated  ||| S:1350 E:1361 ||| VBN
with  ||| S:1361 E:1366 ||| IN
worse  ||| S:1366 E:1372 ||| JJR
DSS  ||| S:1372 E:1376 ||| NNP
( ||| S:1376 E:1377 ||| -LRB-
HR  ||| S:1377 E:1380 ||| NNP
2.09 ||| S:1380 E:1384 ||| NNP
,  ||| S:1384 E:1386 ||| ,
95  ||| S:1386 E:1389 ||| CD
%  ||| S:1389 E:1391 ||| NN
1.31-3.35 ||| S:1391 E:1400 ||| NN
,  ||| S:1400 E:1402 ||| ,
p  ||| S:1402 E:1404 ||| VBG
=  ||| S:1404 E:1406 ||| SYM
0.002 ||| S:1406 E:1411 ||| CD
) ||| S:1411 E:1412 ||| -RRB-
;  ||| S:1412 E:1414 ||| :
however ||| S:1414 E:1421 ||| RB
,  ||| S:1421 E:1423 ||| ,
there  ||| S:1423 E:1429 ||| EX
was  ||| S:1429 E:1433 ||| VBD
no  ||| S:1433 E:1436 ||| DT
significant  ||| S:1436 E:1448 ||| JJ
difference  ||| S:1448 E:1459 ||| NN
between  ||| S:1459 E:1467 ||| IN
TS  ||| S:1467 E:1470 ||| NNP
>  ||| S:1470 E:1472 ||| FW
2-5  ||| S:1472 E:1476 ||| FW
cm  ||| S:1476 E:1479 ||| FW
versus  ||| S:1479 E:1486 ||| FW
≤2  ||| S:1486 E:1489 ||| FW
cm  ||| S:1489 E:1492 ||| FW
( ||| S:1492 E:1493 ||| -LRB-
HR  ||| S:1493 E:1496 ||| NNP
1.25 ||| S:1496 E:1500 ||| CD
,  ||| S:1500 E:1502 ||| ,
95  ||| S:1502 E:1505 ||| CD
%  ||| S:1505 E:1507 ||| NN
0.85-1.83 ||| S:1507 E:1516 ||| NN
,  ||| S:1516 E:1518 ||| ,
p  ||| S:1518 E:1520 ||| VBG
=  ||| S:1520 E:1522 ||| SYM
0.25 ||| S:1522 E:1526 ||| CD
) ||| S:1526 E:1527 ||| -RRB-
.  ||| S:1527 E:1529 ||| .
The  ||| S:1529 E:1533 ||| DT
impact  ||| S:1533 E:1540 ||| NN
of  ||| S:1540 E:1543 ||| IN
TS  ||| S:1543 E:1546 ||| NNP
remained  ||| S:1546 E:1555 ||| VBD
significant  ||| S:1555 E:1567 ||| JJ
on  ||| S:1567 E:1570 ||| IN
DSS  ||| S:1570 E:1574 ||| NNP
in  ||| S:1574 E:1577 ||| IN
subset  ||| S:1577 E:1584 ||| NN
of  ||| S:1584 E:1587 ||| IN
patients  ||| S:1587 E:1596 ||| NNS
who  ||| S:1596 E:1600 ||| WP
underwent  ||| S:1600 E:1610 ||| VBD
lymphadenectomy  ||| S:1610 E:1626 ||| VBN
with  ||| S:1626 E:1631 ||| IN
negative  ||| S:1631 E:1640 ||| JJ
lymph  ||| S:1640 E:1646 ||| JJ
nodes ||| S:1646 E:1651 ||| NN
.  ||| S:1651 E:1653 ||| .
TS  ||| S:1653 E:1656 ||| NNP
was  ||| S:1656 E:1660 ||| VBD
an  ||| S:1660 E:1663 ||| DT
independent  ||| S:1663 E:1675 ||| JJ
predictor  ||| S:1675 E:1685 ||| NN
of  ||| S:1685 E:1688 ||| IN
lymph  ||| S:1688 E:1694 ||| JJ
node  ||| S:1694 E:1699 ||| JJ
metastasis  ||| S:1699 E:1710 ||| NN
and  ||| S:1710 E:1714 ||| CC
disease-specific  ||| S:1714 E:1731 ||| JJ
survival  ||| S:1731 E:1740 ||| NN
in  ||| S:1740 E:1743 ||| IN
patients  ||| S:1743 E:1752 ||| NNS
with  ||| S:1752 E:1757 ||| IN
EEC  ||| S:1757 E:1761 ||| NNP
grossly  ||| S:1761 E:1769 ||| RB
confined  ||| S:1769 E:1778 ||| VBN
to  ||| S:1778 E:1781 ||| TO
the  ||| S:1781 E:1785 ||| DT
uterus ||| S:1785 E:1791 ||| NN
.  ||| S:1791 E:1793 ||| .
Tumor  ||| S:1793 E:1799 ||| NNP
> ||| S:1799 E:1800 ||| CD
5  ||| S:1800 E:1802 ||| CD
cm  ||| S:1802 E:1805 ||| NNS
was  ||| S:1805 E:1809 ||| VBD
a  ||| S:1809 E:1811 ||| DT
predictor  ||| S:1811 E:1821 ||| NN
of  ||| S:1821 E:1824 ||| IN
disease-specific  ||| S:1824 E:1841 ||| JJ
survival  ||| S:1841 E:1850 ||| NN
but  ||| S:1850 E:1854 ||| CC
no  ||| S:1854 E:1857 ||| DT
difference  ||| S:1857 E:1868 ||| NN
in  ||| S:1868 E:1871 ||| IN
outcome  ||| S:1871 E:1879 ||| NN
was  ||| S:1879 E:1883 ||| VBD
noted  ||| S:1883 E:1889 ||| VBN
between  ||| S:1889 E:1897 ||| IN
tumor  ||| S:1897 E:1903 ||| CD
> ||| S:1903 E:1904 ||| CD
2-5  ||| S:1904 E:1908 ||| CD
cm  ||| S:1908 E:1911 ||| NNS
and  ||| S:1911 E:1915 ||| CC
tumor  ||| S:1915 E:1921 ||| NN
≤2  ||| S:1921 E:1924 ||| CD
cm ||| S:1924 E:1926 ||| NNS
.  ||| S:1926 E:1928 ||| .
